We are live on ! Find out more
WST icon

West Pharmaceutical

730 hedge funds and large institutions have $15.3B invested in West Pharmaceutical in 2025 Q2 according to their latest regulatory filings, with 103 funds opening new positions, 269 increasing their positions, 264 reducing their positions, and 80 closing their positions.

New
Increased
Maintained
Reduced
Closed

161% more call options, than puts

Call options by funds: $80M | Put options by funds: $30.7M

29% more first-time investments, than exits

New positions opened: 103 | Existing positions closed: 80

2% more funds holding

Funds holding: 713730 (+17)

2% more repeat investments, than reductions

Existing positions increased: 269 | Existing positions reduced: 264

0.86% more ownership

Funds ownership: 96.64%97.49% (+0.86%)

2% less capital invested

Capital invested by funds: $15.6B → $15.3B (-$338M)

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

Holders
730
Holders Change
+17
Holders Change %
+2.38%
% of All Funds
9.61%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
103
Increased
269
Reduced
264
Closed
80
Calls
$80M
Puts
$30.7M
Net Calls
+$49.3M
Net Calls Change
+$14.3M
Name Holding Trade Value Shares
Change
Change in
Stake
FDCDDQ
401
Federation des caisses Desjardins du Quebec
Quebec, Canada
$579K -$26.3K -123 -4%
OAC
402
OMERS Administration Corp
Ontario, Canada
$578K
LFG
403
Larson Financial Group
Missouri
$570K +$82.1K +384 +17%
SIC
404
Salem Investment Counselors
North Carolina
$558K +$545K +2,550 New
PCA
405
Purkiss Capital Advisors
Connecticut
$551K
PWG
406
Portside Wealth Group
Utah
$550K -$168K -785 -24%
EF
407
Empirical Finance
Pennsylvania
$546K +$4.49K +21 +0.8%
IAA
408
Independent Advisor Alliance
North Carolina
$545K +$20.5K +96 +4%
SW
409
SlateStone Wealth
Florida
$544K -$4.28K -20 -0.8%
VSQM
410
V-Square Quantitative Management
Illinois
$544K +$25.7K +120 +5%
LNWWM
411
Laird Norton Wetherby Wealth Management
California
$535K +$522K +2,444 New
IA
412
Inspire Advisors
Idaho
$532K +$168K +788 +48%
Mercer Global Advisors
413
Mercer Global Advisors
Colorado
$528K +$120K +560 +30%
TC
414
TownSquare Capital
Utah
$527K -$6.77M -31,681 -93%
MA
415
Montag & Associates
Georgia
$520K -$5.13K -24 -1%
SFA
416
Sequoia Financial Advisors
Ohio
$516K +$255K +1,192 +102%
DC
417
Davenport & Co
Virginia
$514K +$25.2K +118 +5%
Carson Wealth (CWM LLC)
418
Carson Wealth (CWM LLC)
Nebraska
$512K +$184K +862 +58%
SBFM
419
S-Bank Fund Management
Finland
$509K -$43.2K -202 -8%
GC
420
Guggenheim Capital
Illinois
$505K -$870K -4,071 -64%
NMIMC
421
Northwestern Mutual Investment Management Company
Wisconsin
$501K -$2.35K -11 -0.5%
CCM
422
Coldstream Capital Management
Washington
$495K +$78.2K +366 +19%
RA
423
RFG Advisory
Alabama
$478K +$61.6K +288 +15%
HCA
424
Hyperion Capital Advisors
New York
$466K
BG
425
Bahl & Gaynor
Ohio
$465K -$42.8K -200 -9%

WST Hedge Fund Activity: Q2 2025 in Review

730 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q2 2025, worth a combined $15.3B — down 2.2% from $15.6B a quarter earlier.

Buyers outnumbered sellers: 103 funds opened new WST positions and 80 closed out — a net gain of 23 holders — while 269 added to existing stakes and 264 trimmed.

The largest buyer was Generation Investment Management, opening a new position worth an estimated $249M. The largest seller was Fidelity Investments, cutting an estimated $136M.

  • 730 institutional investors held West Pharmaceutical (WST) as of Q2 2025, up from 713 in Q1 2025.
  • Funds reported $15.3B of West Pharmaceutical stock for Q2 2025, down 2.2% quarter-over-quarter.
  • 103 funds opened new West Pharmaceutical positions in Q2 2025 and 80 closed out, a net change of +23 holders.
  • The largest West Pharmaceutical buyer in Q2 2025 was Generation Investment Management, an estimated $249M added.
  • The largest West Pharmaceutical seller in Q2 2025 was Fidelity Investments, an estimated $136M sold.

Based on aggregated 13F filings for Q2 2025.